Form 4: AnaptysBio Chief Medical Officer Paul F. Lizzul Reports Stock Transactions

Chief Medical Officer Paul F. Lizzul of AnaptysBio, Inc. reports the exercise of stock options and subsequent sale of shares on September 23, 2024.

Summary

• On September 23, 2024, Paul F. Lizzul, Chief Medical Officer of AnaptysBio, Inc., exercised stock options to acquire 1,500 shares of common stock at a price of $18.50 per share.
• Simultaneously, Lizzul sold 1,500 shares of common stock at $38.67 per share.
• Following these transactions, Lizzul directly owns 15,398 shares of AnaptysBio common stock.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 10, 2024.
• Lizzul also holds options to purchase 85,000 shares of common stock as set forth in Table II, and additional options to purchase up to an aggregate of 297,610 shares of common stock, which options vest according to their terms.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, suggesting they were planned and not based on immediate insider information.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their transactions in company stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in insider ownership.

Key Dates